Denmark· DK-28104713610
Yervoy
A ipilimumab product containing ipilimumab, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ipilimumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX04 (ipilimumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Ipilimumab · ATC L01FX04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ipilimumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ipilimumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$884.82
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Ipilimumab
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L01FX04
- ATC class
- Ipilimumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104713610
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
157 interactions on record for ipilimumab.
Graded by severity as the source publishes them — 25 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ipilimumab · interactions on record
157 records
- 25 severe
- 132 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FX04
Ipilimumab, as other registers publish it.
- NorwayYervoyAbacus Medicine A/S
- NorwayYervoyBristol-Myers Squibb Pharma EEIG
- PolandYervoyBristol-Myers Squibb Pharma EEIG
- IcelandYervoyBristol-Myers Squibb Pharma EEIG*
- FinlandYERVOYOrifarm Oy
- CanadaYERVOYBRISTOL-MYERS SQUIBB CANADA
- United StatesYERVOYE.R. Squibb & Sons, L.L.C.
- United StatesYERVOYE.R. Squibb & Sons, L.L.C.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aa7b1ace-6a1d-45d9-b7ae-bcb7d82adb40 GET /v1/drugs/aa7b1ace-6a1d-45d9-b7ae-bcb7d82adb40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "5 mg/ml",
"auth_role": "MOD",
"dk_drugid": "28104713610",
"substance": "Ipilimumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "40737"
}See everything about ipilimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.